US FDA approval of Nuzolvence® (zoliflodacin), a first-in-class antibiotic for gonorrhoea
16 December 2025
On 12 December 2025, the US FDA approved Nuzolvence® (zoliflodacin), a first-in-class oral antibiotic for gonorrhoea developed by GARDP and Innoviva Specialty Therapeutics (IST). Media outlets around the world covered the news.
New antibiotics hailed as ‘turning point’ in treating drug-resistant gonorrhoea – Read now
New gonorrhea drug is not just a scientific breakthrough but a business one – Read now
FDA Approves First New Gonorrhoea Treatment in Decades Amid Rising Antibiotic Resistance – Read now
F.D.A. Approves Two New Drugs to Treat Gonorrhea – Read now
FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance – Read now
US FDA approves Innoviva’s oral antibiotic for gonorrhea – Read now
Pharma major Dr. Reddy’s to produce and market drug for gonorrhoea granted approval by U.S. FDA – Read now
New antibiotics for gonorrhea could help beat back drug-resistant infections – Read now
New antibiotic could stave off drug-resistant gonorrhoea – Read now
FDA approves first new kind of drug to target gonorrhea in decades – Read now
With strong phase 3 findings, a new antibiotic for gonorrhea is on the horizon – Read now
FDA endorses 2nd new gonorrhea treatment, clearing way for Innoviva’s Nuzolvence – Read now